logo-loader

Invitrocue leads market with disruptive technology and personalised oncology solutions

Last updated: 01:20 20 May 2019 BST, First published: 11:20 19 May 2019 BST

Invitrocue Ltd (ASX:IVQ) chief executive officer Steven Fang speaks to Proactive Investors about the oncology-focused company's development of cancer treatments by testing specific drugs on laboratory-controlled micro-tumours. 
 
"We've been able to take some of these really innovative, disruptive technologies and apply it to the space of being able to create these micro-tumours," says Fang.
 
He continues, "That allows us to test the response of these cancer cells against those specific drugs.
 
"But it's always done individualised - this whole area of personalised oncology is now coming to market."

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

1 hour, 41 minutes ago